Table 3.

Outcome of Patients With Prostate Cancer by BRCA Mutation Status

Group	5-Year Rate	95% CI	Median (years)	95% CI	Log-Rank P
Overall survival
Controls	86.4	84.4 to 88.4	12.9	11.8 to 14	< .001*
BRCA mutation carriers	62.0	49.1 to 74.9	8.1	5 to 11.1
BRCA1 mutation carriers	82.5	60.4 to 100	10.5	6.7 to 14.5	.338†
BRCA2 mutation carriers	57.9	43.4 to 72.4	6.5	3.4 to 9.6	< .001‡
Cause-specific survival
Controls	90.6	88.8 to 92.4	15.7	—	< .001*
BRCA mutation carriers	70.1	57.2 to 83	8.6	6.4 to 10.7
BRCA1 mutation carriers	80.8	56.9 to 100	10.5	—	.200†
BRCA2 mutation carriers	67.9	53.4 to 82.4	8.6	7.7 to 9.5	< .001‡
Cause-specific survival in M0 patients
Controls	96.2	95 to 97.4	—§	—	< .001*
BRCA mutation carriers	81.5	69 to 94	11.3	7.1 to 15.4
BRCA1 mutation carriers	88.9	68.3 to 100	—§	—	.576†
BRCA2 mutation carriers	80.2	65.9 to 94.5	8.8	6.2 to 11.5	< .001‡
Metastasis-free survival in M0 patients
Controls	93.4	91.6 to 95.2	—∥	—	< .001*
BRCA mutation carriers	77.0	62.7 to 91.3	—∥	—
BRCA1 mutation carriers	90.9	73.8 to 100	—∥	—	.801†
BRCA2 mutation carriers	73.1	55.9 to 90.3	10.6	3.6 to 17.6	< .001‡
Cause-specific survival from prostate cancer metastasis
Controls	35.2	28.5 to 41.9	3.4	2.8 to 4.0	.623*
BRCA mutation carriers	22.4	5.2 to 39.6	2.3	2 to 2.5
BRCA1 mutation carriers	37.5	0 to 93.6	2.3	0 to 4.9	.767†
BRCA2 mutation carriers	20.6	2.8 to 38.4	2.3	1.5 to 3.1	.460‡

^*Univariable P value (log-rank test) for all BRCA carriers versus noncarriers.

^†Univariable P value (log-rank test) for BRCA1 carriers versus noncarriers.

^‡Univariable P value (log-rank test) for BRCA2 carriers versus noncarriers.

^§After a median follow-up of 50 months, median CSS_M₀ was not reached.

^∥After a median follow-up of 50 months, median MFS was not reached.